Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

Ling Dong, Huijuan Lv, Wei Li, Zheng Song, Lanfang Li, Shiyong Zhou, Lihua Qiu, Zhengzi Qian, Xianming Liu, Lixia Feng, Bin Meng, Kai Fu, Xi Wang, Qiang Pan-Hammarström, Ping Wang, Xianhuo Wang, Huilai Zhang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Programmed death-1 (PD-1) /programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in tumor cells. The purpose of this study is to investigate whether intracellular AKT/mTOR signaling could be directly activated by PD-1/PD-L1 during the malignant progression in diffuse large B-cell lymphoma (DLBCL). Detection of the expression of PD-L1 and p-AKT by immunohistochemistry (IHC) showed that both proteins were overexpressed in 54% and 48% DLBCL cases, respectively. Spearman test showed that PD-L1 expression was correlated with p-AKT expression (R=0.244, χ2=5.962; P=0.017) and the expression of PD-L1 and p-AKT were also correlated with clinic-pathological characteristics. In addition, survival analysis showed that DLBCL patients who co-expressed PDL1 and p-AKT had significantly poorer outcome than patients with single positive or both negative expression (P

Original languageEnglish (US)
Pages (from-to)33350-33362
Number of pages13
JournalOncotarget
Volume7
Issue number22
DOIs
StatePublished - May 31 2016

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Ligands
Neoplasms
Tumor Escape
Survival Analysis
Immunohistochemistry
T-Lymphocytes

Keywords

  • AKT/mTOR signaling
  • DLBCL
  • p-AKT
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology

Cite this

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. / Dong, Ling; Lv, Huijuan; Li, Wei; Song, Zheng; Li, Lanfang; Zhou, Shiyong; Qiu, Lihua; Qian, Zhengzi; Liu, Xianming; Feng, Lixia; Meng, Bin; Fu, Kai; Wang, Xi; Pan-Hammarström, Qiang; Wang, Ping; Wang, Xianhuo; Zhang, Huilai.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 33350-33362.

Research output: Contribution to journalArticle

Dong, L, Lv, H, Li, W, Song, Z, Li, L, Zhou, S, Qiu, L, Qian, Z, Liu, X, Feng, L, Meng, B, Fu, K, Wang, X, Pan-Hammarström, Q, Wang, P, Wang, X & Zhang, H 2016, 'Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells', Oncotarget, vol. 7, no. 22, pp. 33350-33362. https://doi.org/10.18632/oncotarget.9061
Dong, Ling ; Lv, Huijuan ; Li, Wei ; Song, Zheng ; Li, Lanfang ; Zhou, Shiyong ; Qiu, Lihua ; Qian, Zhengzi ; Liu, Xianming ; Feng, Lixia ; Meng, Bin ; Fu, Kai ; Wang, Xi ; Pan-Hammarström, Qiang ; Wang, Ping ; Wang, Xianhuo ; Zhang, Huilai. / Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 33350-33362.
@article{6d9b69147ad34927ad27ff54ffb6b2a5,
title = "Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells",
abstract = "Programmed death-1 (PD-1) /programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in tumor cells. The purpose of this study is to investigate whether intracellular AKT/mTOR signaling could be directly activated by PD-1/PD-L1 during the malignant progression in diffuse large B-cell lymphoma (DLBCL). Detection of the expression of PD-L1 and p-AKT by immunohistochemistry (IHC) showed that both proteins were overexpressed in 54{\%} and 48{\%} DLBCL cases, respectively. Spearman test showed that PD-L1 expression was correlated with p-AKT expression (R=0.244, χ2=5.962; P=0.017) and the expression of PD-L1 and p-AKT were also correlated with clinic-pathological characteristics. In addition, survival analysis showed that DLBCL patients who co-expressed PDL1 and p-AKT had significantly poorer outcome than patients with single positive or both negative expression (P",
keywords = "AKT/mTOR signaling, DLBCL, p-AKT, PD-1, PD-L1",
author = "Ling Dong and Huijuan Lv and Wei Li and Zheng Song and Lanfang Li and Shiyong Zhou and Lihua Qiu and Zhengzi Qian and Xianming Liu and Lixia Feng and Bin Meng and Kai Fu and Xi Wang and Qiang Pan-Hammarstr{\"o}m and Ping Wang and Xianhuo Wang and Huilai Zhang",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.9061",
language = "English (US)",
volume = "7",
pages = "33350--33362",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

AU - Dong, Ling

AU - Lv, Huijuan

AU - Li, Wei

AU - Song, Zheng

AU - Li, Lanfang

AU - Zhou, Shiyong

AU - Qiu, Lihua

AU - Qian, Zhengzi

AU - Liu, Xianming

AU - Feng, Lixia

AU - Meng, Bin

AU - Fu, Kai

AU - Wang, Xi

AU - Pan-Hammarström, Qiang

AU - Wang, Ping

AU - Wang, Xianhuo

AU - Zhang, Huilai

PY - 2016/5/31

Y1 - 2016/5/31

N2 - Programmed death-1 (PD-1) /programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in tumor cells. The purpose of this study is to investigate whether intracellular AKT/mTOR signaling could be directly activated by PD-1/PD-L1 during the malignant progression in diffuse large B-cell lymphoma (DLBCL). Detection of the expression of PD-L1 and p-AKT by immunohistochemistry (IHC) showed that both proteins were overexpressed in 54% and 48% DLBCL cases, respectively. Spearman test showed that PD-L1 expression was correlated with p-AKT expression (R=0.244, χ2=5.962; P=0.017) and the expression of PD-L1 and p-AKT were also correlated with clinic-pathological characteristics. In addition, survival analysis showed that DLBCL patients who co-expressed PDL1 and p-AKT had significantly poorer outcome than patients with single positive or both negative expression (P

AB - Programmed death-1 (PD-1) /programmed death-ligand 1 (PD-L1) engagement usually leads to diminished antitumor T-cell responses, which mediates the immune escape of tumor cells. However, little is known whether PD-1/PD-L1 could directly activates intracellular oncogenic signaling pathways in tumor cells. The purpose of this study is to investigate whether intracellular AKT/mTOR signaling could be directly activated by PD-1/PD-L1 during the malignant progression in diffuse large B-cell lymphoma (DLBCL). Detection of the expression of PD-L1 and p-AKT by immunohistochemistry (IHC) showed that both proteins were overexpressed in 54% and 48% DLBCL cases, respectively. Spearman test showed that PD-L1 expression was correlated with p-AKT expression (R=0.244, χ2=5.962; P=0.017) and the expression of PD-L1 and p-AKT were also correlated with clinic-pathological characteristics. In addition, survival analysis showed that DLBCL patients who co-expressed PDL1 and p-AKT had significantly poorer outcome than patients with single positive or both negative expression (P

KW - AKT/mTOR signaling

KW - DLBCL

KW - p-AKT

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=84973577137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973577137&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9061

DO - 10.18632/oncotarget.9061

M3 - Article

VL - 7

SP - 33350

EP - 33362

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -